標的療法市場：タイプ、作用機序、流通チャネル、治療領域別-2025-2030年の世界予測

標的療法市場は、2023年に627億5,000万米ドルと評価され、2024年には671億6,000万米ドルに達すると予測され、CAGR 7.44％で成長し、2030年には1,037億5,000万米ドルに達すると予測されています。

標的療法は、がん治療の革新的な形態であり、通常、正常細胞を傷つけることなく、薬剤やその他の物質を用いてがん細胞を正確に識別し攻撃します。このアプローチでは、がんの分子的・遺伝的基盤を深く理解する必要があり、腫瘍の成長と進行に関与する特定の分子を標的とします。用途はさまざまな種類のがんに及び、個人の遺伝子プロファイルに合わせた治療を行う個別化医療が重視されるようになってきています。最終用途分野には、病院の腫瘍科、専門のがん治療センター、研究機関などが含まれます。

市場の洞察によると、標的療法の成長は、がん罹患率の上昇、ゲノム技術の進歩、精密医療に対する需要の高まりに大きく影響されています。がん研究に対する政府の支援がこの市場をさらに後押ししています。企業は一貫して技術革新を続け、副作用を最小限に抑えながら治療の特異性と有効性の向上を目指しています。最新のビジネスチャンスは、新規バイオマーカーとコンパニオン診断薬の開発にあり、個別化治療計画を推進します。このような機会を活用するため、企業は研究開発協力に投資し、医薬品パイプラインのポートフォリオを拡大する必要があります。

しかし、開発・治療コストの高さ、規制上のハードル、複雑な臨床試験プロセスなどの課題も残っています。さらに、標的治療薬に対する耐性が生じ、長期的な有効性が低下する可能性もあります。腫瘍遺伝学の複雑さも、標的を正確に特定する上での課題となっており、継続的な調査と既存の治療法の改良が必要となっています。

技術革新と研究努力は、既存療法の適応拡大、相乗的併用療法の探求、創薬のための人工知能の活用に重点を置くべきです。市場は競争が激しくダイナミックであるため、企業は適応力を維持し、成長を維持するために継続的なイノベーションと市場志向の研究を重視しなければならないです。要するに、市場の性質上、俊敏性が求められるのであり、企業は競争力を維持するために、技術の進歩や消費者のニーズの変化に迅速に適応する必要があります。

市場力学：急速に進化する標的療法市場の主要市場インサイトを公開

標的療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のがん感受性の有病率の増加
  • 地域全体における医薬品開発への投資の増加
  • がん治療に関する規制の枠組みやガイドラインの改善
• 市場抑制要因
  • 治療に伴う高コスト
• 市場機会
  • 個別化医療のための併用療法への注目の高まり
  • 次世代シーケンサー（NGS）やCRISPRによる遺伝子解析技術の進歩
• 市場の課題
  • 標的治療に対する患者の反応のばらつき

ポーターの5つの力：標的療法市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：標的療法市場における外部からの影響の把握

外部マクロ環境要因は、標的療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析標的療法市場における競合情勢の把握

標的療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス標的療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、標的療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨標的療法市場における成功への道筋を描く

標的療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的にがん罹患率が上昇
    • 地域をまたいで医薬品開発への投資が増加
    • がん治療に関する規制枠組みとガイドラインの改善
  • 抑制要因
    • 治療にかかる高額な費用
  • 機会
    • 個別化医療のための併用療法への注目の高まり
    • 遺伝子構造解析のための次世代シーケンシング（NGS）とCRISPRの技術的進歩
  • 課題
    • 標的療法に対する患者の反応のばらつき
• 市場セグメンテーション分析
  • タイプ：個別化医療におけるモノクローナル抗体の利用拡大
  • 治療領域：多額の投資による肺がん治療の急速な導入
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 標的療法市場：タイプ別

• モノクローナル抗体
• 低分子医薬品

第7章 標的療法市場作用機序別

• 血管新生阻害剤
• アポトーシス誘導剤
• 遺伝子発現調節剤
• ホルモン療法
• シグナル伝達阻害剤

第8章 標的療法市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 標的療法市場治療領域別

• 乳がん
• 大腸がん
• 白血病
• 肺がん
• リンパ腫
• 多発性硬化症
• 腎臓がん

第10章 南北アメリカの標的療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の標的療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの標的療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ノバルティス、マリアナ・オンコロジーの買収でがん治療の武器を強化
  • デルフィア・バイオテック、がん細胞を標的にして殺す革新的なアプローチを発表
  • ノバルティス、インドで慢性骨髄性白血病の新薬を発売、患者に改善された治療オプションを提供
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• BeiGene, Ltd.
• Biogen Inc.
• BioMarin Pharmaceutical Inc.
• Bristol Myers Squibb Company
• Eisai Co., Ltd.
• Eli Lilly and Company
• Exelixis, Inc.
• F. Hoffmann-La Roche AG
• Genmab A/S
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Incyte Corporation
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. TARGETED THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. TARGETED THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TARGETED THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE MEDICINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY APOPTOSIS INDUCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY GENE EXPRESSION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY HORMONE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY SIGNAL TRANSDUCTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 41. CANADA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 43. CANADA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. CANADA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 63. CHINA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CHINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 65. CHINA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. CHINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 67. INDIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 69. INDIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. INDIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 136. ITALY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. ITALY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 138. ITALY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. ITALY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 152. POLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. POLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 154. POLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. POLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 156. QATAR TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. QATAR TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 158. QATAR TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. QATAR TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 196. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Targeted Therapy Market was valued at USD 62.75 billion in 2023, expected to reach USD 67.16 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 103.75 billion by 2030.

Targeted therapy is an innovative form of cancer treatment that uses drugs or other substances to precisely identify and attack cancer cells, usually without harming normal cells. This approach necessitates a deep understanding of the molecular and genetic bases of cancer, targeting specific molecules involved in tumor growth and progression. Applications range across various types of cancers, with a growing emphasis on personalized medicine, where treatments are tailored to individual genetic profiles. End-use sectors prominently include oncology departments in hospitals, specialized cancer treatment centers, and research institutions.

Market insights reveal targeted therapy's growth is significantly influenced by rising cancer prevalence, advances in genomic technologies, and increasing demand for precision medicine. Government support for cancer research further bolsters this market. Companies are consistently innovating, aiming to improve the specificity and efficacy of treatments while minimizing side effects. The latest opportunities lie in the development of novel biomarkers and companion diagnostics, propelling personalized treatment plans. To capitalize on these opportunities, firms should invest in R&D collaborations and broaden their drug pipeline portfolios.

However, challenges persist, such as the high costs of development and treatment, regulatory hurdles, and complex clinical trial processes. Additionally, resistance to targeted therapies can develop, leading to reduced long-term efficacy. The intricacies of tumor genetics also pose challenges in accurately identifying targets, necessitating ongoing research and refinement of existing therapies.

Innovation and research efforts should focus on expanding indications for existing therapies, exploring synergistic combination treatments, and leveraging artificial intelligence for drug discovery. As the market is highly competitive and dynamic, businesses must remain adaptable, emphasizing continuous innovation and market-oriented research to sustain growth. In essence, the nature of the market demands agility, with companies needing to swiftly adapt to technological advancements and evolving consumer demands to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Targeted Therapy Market

The Targeted Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancer susceptibility globally
  • Rising investment in drug development across geographies
  • Improved regulatory frameworks and guidelines for cancer treatment
• Market Restraints
  • High cost associated with treatment
• Market Opportunities
  • Increased focus on combination therapies for personalized medicine
  • Technological advancements in next-generation sequencing (NGS) and CRISPR for genetic makeup
• Market Challenges
  • Variability in patient response to targeted therapies

Porter's Five Forces: A Strategic Tool for Navigating the Targeted Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Targeted Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Targeted Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Targeted Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Targeted Therapy Market

A detailed market share analysis in the Targeted Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Targeted Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Targeted Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Targeted Therapy Market

A strategic analysis of the Targeted Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Targeted Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Ltd., Biogen Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Monoclonal Antibodies and Small Molecule Medicines.
• Based on Mechanism of Action, market is studied across Angiogenesis Inhibitors, Apoptosis Inducers, Gene Expression Modulators, Hormone Therapies, and Signal Transduction Inhibitors.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Therapeutic Area, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, and Renal Cancer.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer susceptibility globally
    • 5.1.1.2. Rising investment in drug development across geographies
    • 5.1.1.3. Improved regulatory frameworks and guidelines for cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased focus on combination therapies for personalized medicine
    • 5.1.3.2. Technological advancements in next-generation sequencing (NGS) and CRISPR for genetic makeup
  • 5.1.4. Challenges
    • 5.1.4.1. Variability in patient response to targeted therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Expanding usage of monoclonal antibodies for personalized medicine
  • 5.2.2. Therapeutic Area: Rapid adoption of lung cancer therapies with substantial investment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Targeted Therapy Market, by Type

• 6.1. Introduction
• 6.2. Monoclonal Antibodies
• 6.3. Small Molecule Medicines

7. Targeted Therapy Market, by Mechanism of Action

• 7.1. Introduction
• 7.2. Angiogenesis Inhibitors
• 7.3. Apoptosis Inducers
• 7.4. Gene Expression Modulators
• 7.5. Hormone Therapies
• 7.6. Signal Transduction Inhibitors

8. Targeted Therapy Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Targeted Therapy Market, by Therapeutic Area

• 9.1. Introduction
• 9.2. Breast Cancer
• 9.3. Colorectal Cancer
• 9.4. Leukemia
• 9.5. Lung Cancer
• 9.6. Lymphoma
• 9.7. Multiple Sclerosis
• 9.8. Renal Cancer

10. Americas Targeted Therapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Targeted Therapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Targeted Therapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Novartis Strengthens Cancer Treatment Arsenal with Acquisition of Mariana Oncology
  • 13.3.2. Delphia Biotech Introduces Launched a Revolutionary Approach Targeting and Killing Cancer Cells
  • 13.3.3. Novartis to Launch New Chronic Myeloid Leukemia Drug in India, Offering Improved Treatment Options for Patients
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. BeiGene, Ltd.
• 7. Biogen Inc.
• 8. BioMarin Pharmaceutical Inc.
• 9. Bristol Myers Squibb Company
• 10. Eisai Co., Ltd.
• 11. Eli Lilly and Company
• 12. Exelixis, Inc.
• 13. F. Hoffmann-La Roche AG
• 14. Genmab A/S
• 15. Gilead Sciences, Inc.
• 16. GlaxoSmithKline plc
• 17. Incyte Corporation
• 18. Johnson & Johnson Services, Inc.
• 19. Merck & Co., Inc.
• 20. Merck KGaA
• 21. Novartis AG
• 22. Pfizer Inc.
• 23. Regeneron Pharmaceuticals, Inc.
• 24. Sanofi S.A.
• 25. Takeda Pharmaceutical Company Limited